MAPT and Alzheimer disease: Notably, these studies demonstrated that OMdP in bEVs possess the ability to interact with regions of human proteins that are directly involved in proteinopathy and neurotoxicity in AD neuropathology in 95% of the simulated cases involving the proteins APP, TAU, and PrP (Fig. 6, L–N), whereas in 75% of the simulated cases involving PSEN1 (Fig. 6O).